Abstract
Background To date, there is a spread of resistance of microorganisms to antibiotics. To solve this problem, the search and development of new drugs with antibacterial activity is necessary. Antimicrobial peptides (AMPs) have pronounced antibacterial activity and may be promising candidates for the role of new drugs. Besides, AMPs can be used to overcome conventional antibiotics resistance due to the possible synergistic effect. In this work, the combined effect of some AMPs (human defensins, HNP-1, hBD-1, hBD-3 and cathelicidin, LL-37) with conventional antibiotics (vancomycin and imipenem) against gram-positive (Enterococcus faecalis; Staphylococcus aureus, methicillin-sensitive, MSSA, and methicillin-resistant, MRSA) and gram-negative (Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa) bacterial strains was investigated.
Methods Bacterial strains were isolated from hospitalized patients of the intensive care unit. Commercially available AMPs (HNP-1, hBD-1, hBD-3, LL-37 by Cloud-Clone Corp., USA) and antibiotics, vancomycin (Sandoz, Slovenia) and imipenem (Merck Sharp and Dohme, USA) were used. Antibiotic resistance phenotypes of isolated bacterial strains were carried out using the disk diffusion method. The standard checkerboard assays were used to study minimum inhibitory concentrations (MIC) of antimicrobials. The combined microbicidal effect of two substances (AMP+conventional antibiotic) was assessed by the fractional inhibitory concentration index (FICI). If FICI ≤ 0,5, then it was considered that two substances showed synergism of action; if 0.5 < FICI < 4 – no interaction; if FICI > 4 – antagonism.
Results All studied AMPs had antibacterial activity against the studied strains. hBD-3 showed the lowest MICs compared to other AMPs. MIC of hBD-3 against S. aureus (MSSA and MRSA), E. coli, K. pneumoniae was the same – 0.5 mg/L, and against P. aeruginosa it was 2 mg/L. The combinations HNP-1+vancomycin (against E. faecalis) and hBD-3+imipenem (against E. coli, K. pneumoniae, P. aeruginosa) according to FICI values have shown the synergistic effect. The results of this study can be used to develop novel antibiotics based on AMPs. Also, in some cases, AMPs can help to overcome resistance to conventional antibiotics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Russian Foundation for Basic Research according to the research project No. 18-315-00081
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All of the data referred to in the manuscript is available
